Explore Our Network

4TEEN4 Pharmaceuticals GmbH is a German biotech company pioneering precision medicine in critical care, with a mission to develop causal therapies for acute cardiovascular complications, particularly shock. The company focuses on targeting cDPP3, a key mediator in circulatory failure, and is advancing Procizumab, a first-in-class antibody, through clinical development. With a leadership team boasting over 150 years of pharma experience and a strong network of international researchers, 4TEEN4 aims to address unmet medical needs and improve patient outcomes where current therapies are inadequate.

AbViro is a Phase 2 clinical stage biotech company developing monoclonal antibody therapeutics for infectious diseases.

Advanced BioScience Laboratories, Inc. (ABL) is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics, and other biologic products. ABL leverages its expertise in product development, GMP manufacturing, and immunological testing to support the development of candidate vaccines and therapeutics through preclinical and clinical stages. The company is involved in producing and testing oncolytic viruses, gene therapies, immunotherapies, viral vaccines, and recombinant protein vaccines.

Advanced Light Devices manufactures the patent pending Hemealumen Polychromatic Device Innovative Solutions for Treating Infectious and Neurodegenerative Diseases Company Overview Advanced Light Devices is a pioneering company established in the early 2000s, dedicated to developing advanced medical technologies for the treatment of a range of diseases. With a vision to revolutionize healthcare, the company focuses on innovative therapies that utilize light-based technology to address complex medical challenges. The Hemealumen Polychromatic Device At the core of Advanced Light Devices' portfolio is the Hemealumen Polychromatic Device, a state-of-the-art medical tool designed to combat both viral and bacterial diseases. In addition, this device is being used as a therapeutic option for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. Applications in Infectious Disease Treatment The Hemealumen Polychromatic Device has demonstrated effectiveness in treating a variety of infectious diseases, including: Malaria Dengue fever COVID-19 Zika virus Shingles By utilizing targeted polychromatic light, the device disrupts the replication and survival mechanisms of pathogens, offering a non-invasive and innovative approach to disease management. Blood Treatment During Transfusions The Hemealumen Polychromatic Device is also used to treat blood during transfusions, effectively eliminating bacteria and viruses. This process enhances the safety of blood transfusions, reducing the risk of transfusion-transmitted infections and improving patient outcomes. Impact on Neurodegenerative Diseases Beyond infectious diseases, the device shows promise in the management of neurodegenerative conditions such as ALS and Parkinson's disease. Its mechanism of action may help reduce the progression of these disorders, though further research is ongoing to fully understand its therapeutic potential. Conclusion Advanced Light Devices, through the Hemealumen Polychromatic Device, is at the forefront of medical innovation. Their commitment to developing effective treatments for both infectious and neurodegenerative diseases position them as a leader in the field of light-based medical technology.

Advanced Virology specializes in high-fidelity production and engineering of research-grade virus stocks using reverse genetics. The company supports customizable solutions across a broad range of viral families—including wild-type, chimeric, and reporter-expressing viruses. Comprehensive quality assurance and documentation protocols are applied to each batch. Custom services enable the development of tailored virus variants, molecular tags, and reporters to meet research and assay needs.

Akthelia Pharmaceuticals is a pioneering biopharmaceutical company focused on developing therapeutics that enhance the body's innate defense mechanisms to combat debilitating diseases. The company targets mucosal barrier injury and epithelial integrity through a novel immunotherapeutic strategy. Its mission is to revolutionize treatment for diseases such as cancer, infection, and autoimmune disorders by leveraging the body's own microbial defense mechanisms.

Allvivo Vascular is a biomedical company dedicated to developing innovative tissue regenerative and antimicrobial technologies aimed at reducing infections associated with medical devices and wounds. With a commitment to improving patient outcomes and healthcare economics, Allvivo collaborates with partners to deliver more effective treatment options.

Aluda Pharmaceuticals develops novel small molecule therapeutics for severe immune and fibrotic diseases, utilizing a systems biology approach targeting under-recognized and complex disease mechanisms. The company focuses on discovery and development of new molecular entities aimed at key regulatory proteins such as vimentin and STAT3, leveraging expertise in phenotypic screening, network-driven biology, and translational science. Aluda's pipeline addresses unmet needs in autoimmune, fibrotic, and refractory cancer conditions, with a scientific foundation in deep cell biology and state-of-the-art discovery methods.

Ambient Biosciences is a global leader in biostabilization, dedicated to eliminating cold chain reliance and improving global health equity through innovative biomolecule stabilization technology. Their patented Capillary-Assisted Vitrification (CAV) process enables room-temperature storage and shipping of sensitive reagents and biomolecules, offering a superior alternative to traditional lyophilization and cryopreservation. With a values-driven, diverse team of scientific experts and visionary leaders, Ambient Biosciences is committed to transforming laboratory operations, reducing costs and waste, and making life sciences more accessible and sustainable worldwide.

Anamed, Inc. is a medical device company with the mission of making everyday procedures, easier - Specifically addressing challenges in regional anesthesia, airway management, and ultrasound imaging. The flagship product centers on improving the safety, efficiency, and effectiveness of video laryngoscope intubation - enabling reliable single-operator airway securement.

AperionDx develops scalable, ultra-sensitive protein diagnostic technologies leveraging standard qPCR instruments. The company's solutions enable rapid, accurate, and cost-effective detection of disease biomarkers from blood samples, supporting clinical research, drug development, and potential clinical diagnostics, with a focus on neurological diseases like traumatic brain injury and Alzheimer's disease. AperionDx emphasizes accessibility and scalability for laboratories and clinics while continually expanding applications for its technology.

Aphios is a green biotechnology company focused on developing enabling nanotechnology platforms and enhanced therapeutics for health maintenance, disease prevention, and treatment of various conditions including cancers, infectious diseases, and central nervous system (CNS) disorders. The company emphasizes environmentally-sustainable practices and aims to improve the quality of life through innovative therapies.

ARIScience is at the forefront of drug discovery, leveraging a unique combination of AI, quantum chemistry, computer vision, and biochemistry to develop novel small molecule drugs. Their mission is to reduce the burden of human disease by discovering therapeutics that interrupt disease pathways. With a focus on neurodegenerative, inflammatory, and infectious diseases, ARIScience employs cutting-edge in silico methods to efficiently identify and optimize drug candidates. Their commitment to innovation and collaboration with leading institutions positions them to make a significant impact on human health. ARIScience is creating value in two ways: Value 1: ARIScience is developing small molecule assets targeting respiratory depression, cutaneous burn and radiation injuries, antivirals for EBOV and DENV, bacteriostatic antibiotic targeting Staph aureus. Value 2: It's novel AI driven quasi quantum chemistry (AI+QQ) small molecule discovery platform for precision protein inhibition and potentiation.

Arizona State University (ASU) is a comprehensive public research university known for its commitment to inclusivity, excellence, and societal impact. ASU is dedicated to advancing research-based solutions for global challenges, fostering strong leadership, and providing quality education accessible to all learners. The university is recognized for its innovative approach to education and its efforts in sustainability, research, and community service. ASU exemplifies a new prototype for the American public research university, focusing on excellence, broad access to quality education, and meaningful societal impact.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.

Arnav Biotech is an mRNA manufacturing and contract research company focused on developing high-quality, custom mRNA for therapeutic, vaccine, diagnostic, and agricultural applications. The company aims to support academic and industry scientists in developing mRNA-based therapeutics and vaccines through expert design and optimization.

Aspen Medical is a global leader in innovative healthcare solutions, specializing in delivering high-quality healthcare services in remote, challenging, and under-resourced environments. Established in 2003 in Australia, the company operates across Australia, the UK and Europe, the Middle East, North America, Africa, Asia, and the Indo-Pacific region. Aspen Medical is the only commercial organization in the world certified by the World Health Organization as an Emergency Medical Team for infectious disease outbreaks and trauma surgical operations. The company is committed to social responsibility, diversity, and inclusion, and is a certified B Corp and a signatory to the United Nations Global Compact. Aspen Medical partners with governments, NGOs, and private sector clients to provide end-to-end healthcare solutions, including hospitals and clinics, health advisory services, humanitarian and disaster response, aeromedical retrievals, occupational health, training, health technology, aged care, and medical equipment supply. The Aspen Medical Foundation, the company's registered charity, supports scholarships, community partnerships, and philanthropic initiatives, with a focus on empowering healthcare workers and communities.

ATD Emolda has been delivering innovative solutions for 40 years, specializing in the conversion and manufacturing of components and assemblies for industrial, medical, and pharmaceutical applications. The company has become a thought leader in advanced wound care materials, focusing on developing high-performance polyurethane foams and silicone adhesives.

Athari BioSciences is a CLIA-certified BSL-2 diagnostic, research, and training laboratory advancing healthcare through scientific innovation in diagnostics, therapeutics, genomic research, and workforce development. With a mission focused on improving health equity, personalized medicine, and education, the company provides laboratory, research, and regulatory services, and offers hands-on learning experiences to foster the next generation of life sciences professionals.

Athena GTX is dedicated to advancing wireless, mobile, patient-worn monitoring solutions for both military and civilian markets. The company focuses on connecting patients and providers through state-of-the-art medical and communication technology, developed and produced in Iowa. Athena GTX aims to enhance patient outcomes by integrating innovative wireless technology with reliable devices, supporting first responders and medical professionals in various challenging environments.

Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.